# A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Source: https://onco.cc/trials/nct03602859/  
OnCo record `nct03602859` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Niraparib and Dostarlimab in ovarian cancer, run by Tesaro, Inc., active and no longer recruiting.

## Summary

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer is a phase 3 interventional study registered as NCT03602859 by Tesaro, Inc., with 1400 participants enrolled, started 2018-10-11 and due to reach its primary completion in 2024-10-31. Interventions recorded: Niraparib, Dostarlimab (TSR-042), Standard of care, Dostarlimab-Placebo and Niraparib-Placebo. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03602859
- Phase: 3
- Setting: A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
- Sponsor: Tesaro, Inc.
- Enrolled: 1400
- Outcomes: Progression Free Survival (PFS): Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) 19.19 months vs Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) 20.63 months, HR 0.85; Overall Survival (OS): Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) 45.37 months vs Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) 44.39 months; Objective Response Rate (ORR): Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) 88% vs Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) 88.4%

## Sources

- ClinicalTrials.gov NCT03602859: https://clinicaltrials.gov/study/NCT03602859

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/), [Niraparib](https://onco.cc/drugs/niraparib/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct03602859.json